WBP1L pseudogene 8 (WBP1LP8)

WBP1L pseudogene 8 (WBP1LP8) is annotated as a pseudogene in human genomic databases and is part of the gene family related to WW domain binding protein 1-like (WBP1L), which itself is a transmembrane adaptor protein involved in the regulation of hematopoietic stem cell function and immune cell development[1][2]. However, WBP1LP8 does not encode a known functional protein and lacks evidence of biological activity, pharmacological relevance, or disease association. There is no information establishing it as a receptor, enzyme, transporter, transcription factor, or any other druggable class. No drugs, mechanisms, or biomarkers are associated with WBP1LP8. It is not referenced in clinical, functional, or mechanistic literature as a therapeutic target. Most resources mentioning WBP1LP8 simply note its status as a pseudogene and provide basic genomic annotation[5]. The parent gene, WBP1L (WW domain binding protein 1-like, also known as OPAL1), is a functionally relevant protein involved in hematopoiesis, T cell development, and regulation of key immune signaling pathways[1][2]. WBP1L is correlated with prognosis in leukemia and ovarian cancer, acts as a regulator of stem and progenitor cell proliferation, and interacts with chemokine receptors and ubiquitin ligases[1][2]. However, none of these properties or disease associations extend to WBP1LP8, which remains an uncharacterized pseudogene without established function or therapeutic value[5]. If information sought regards a drug target, receptor, or biologically active protein, consider refocusing to the functional parent gene “WBP1L (WW domain binding protein 1-like)” rather than “WBP1L pseudogene 8.”

Other names

WBP1LP8WBP1L Pseudogene 8